Claims for Patent: 6,217,893

Summary for Patent: 6,217,893

Title:	Sustained-release compositions and method for preparing same
Abstract:	The invention relates to compositions in the form of microcapsules or implants comprising a biodegradable polymeric or copolymeric excipient or a mixture of such excipients with an inherent viscosity of between 0.5 dl/g and 1.6 dl/g in CHCl.sub.3, and one active substance or a mixture of active substances, it being possible for said microcapsules or implants to release the active substance or mixture of active substances over a prolonged period of up to three months or more. These compositions may also comprise an active principle having a high specific surface area.
Inventor(s):	Pellet; Marc (Conde sur Iton, FR), Roume; Chantal (Signon, FR)
Assignee:	Pharma Biotech (FR)
Application Number:	09/403,058
Patent Claims:	1. A composition in the form of microcapsules or an implant comprising at least one member selected from the group consisting of a biodegradable polymeric excipient and a biodegradable copolymeric excipient and at least one active substance for prolonged release of the active substance over up to more than 3 months according to an essentially monophase release profile, wherein in the case of microcapsules, the excipients comprise a copolymer having a viscosity of 0.9 to 1.6 dl/g in CHCl.sub.3 and the preparation process for said microcapsules does not comprise any fusion stage and in the case of an implant, the excipient has a viscosity of 0.5 to 1.6 dl/g in CHCl.sub.3. 2. A composition of claim 1 wherein the excipient has a viscosity of at least 0.9 dl/g. 3. A composition of claim 1 wherein the excipient is a copolymer of lactide and glycolide (PLGA). 4. A composition of claim 3 wherein the excipient has an acid number greater than 1 meq of KOH per gram of excipient. 5. A composition of claim 4 wherein the acid number is greater than 1.2 meq. 6. A composition of claim 4 wherein the acid number is greater than 1.5 meq. 7. A composition of claim 3 wherein the PLGA is 70 to 80% of lactide and 20 to 30% of glycolide. 8. A composition of claim 1 wherein the excipient is a copolymer of L-lactide and glycolide. 9. A composition of claim 1 wherein the active substance is at least one water-soluble substance of high specific surface area. 10. A composition of claim 9 wherein the specific surface area is greater than 2 m.sup.2 /g. 11. A composition of claim 9 wherein the specific surface area is greater than 3 m.sup.2 /g. 12. A composition of claim 9 wherein the specific surface area is greater than 30 m.sup.2 /g. 13. A composition of claim 9 wherein the viscosity of the excipient is 0.5 to 1.6 dl/g. 14. A composition of claim 9 wherein the excipient has an acid number greater than 1 meq of KOH per gram of excipient. 15. A composition of claim 9 wherein the excipient is a copolymer of lactide and glycoside (PLGA). 16. A composition of claim 1 wherein the active substance is a protein or a peptide. 17. A composition of claim 1 wherein the active substance is selected from the group consisting of triptorelin and its salts, triptorelin acetate, lanreotide and one of its salts and its acetate, octreotide and its salts, a compound with LH-RH activity, an LH-RH antagonist, a GPIIb/IIIa antagonist, a compound with a similar activity to GPIIb/IIIa antagonist, erythropoietin (EPO) and one of its analogues, various types of interferon-.alpha., interferon-.beta. or -.gamma., somatostatin, a somatostatin derivative, a somatostatin analogue, insulin, a growth hormone, a growth hormone releasing factor (GRF), a growth hormone releasing peptide (GHRP), an epidermal growth factor (EGF), a melanocyte stimulating hormone (MSH), a thyrotropin releasing hormone (TRH) and its salts and derivatives, a thyroid stimulating hormone (TSH), a luteinizing hormone (LH), a follicle stimulating hormone (FSH), a parathyroid hormone (PTH) and its derivatives, a lysozyme hydrochloride, a parathyroid hormone related peptide (PTHrp), an N-terminal peptide fragment (position 1->34) of human PTH hormone, vasopressin and its derivatives, oxytocin, calcitonin, calcitonin derivative with a similar activity to that of calcitonin, a calcitonin gene related peptide (CGRP), glucagon, a peptide similar to glucagon (GLP), gastrin, a gastrin releasing peptide (GRP), secretin, pancreozymin, cholecystokinin, angiotensin, human placental lactogen, human chorionic gonadotropin (HCG), enkephalin, an enkephalin derivative, colony stimulating factor (CSF), endorphin, kyotorphin, interleukins, tuftsin, thymopoietin, thymosthymlin, thymic humoral factor (THF), thymic serum factor (TSF), a derivative of thymic serum factor (TSF), thymosin, thymic factor X, tumor necrosis factor (TNF), motilin, bombesin and its derivatives, prolactin, neurotensin, dynorphin, caerulein, substance P, urokinase, asparaginase, bradykinin, kallikrein, nerve growth factor, a blood clotting factor, polymixin B, colistin, gramicidin, bacitracin, a protein synthesis stimulating peptide, an endothelin antagonist and its salts and derivatives, a vasoactive intestinal polypeptide (VIP), adrenocorticotropic hormone (ACTH) or one of its fragments, a platelet derived growth factor (PDGF), a bone morphogenetic protein (BMP), a pituitary adenylate cyclase activating polypeptide (PACAP), neuropeptide Y (NPY), peptide YY (PYY), a gastric inhibitory polypeptide (GIP) and polynucleotides. 18. A composition of claim 1 wherein the active substance is selected from the group consisting of triptorelin acetate, lanreotide acetate and octreotide acetate.

Details for Patent 6,217,893

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2017-04-18
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2017-04-18
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2017-04-18
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		2017-04-18